secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001493152-24-034714
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PowerUp Acquisition announces definitive merger with Aspire Biopharma at $316M pre-money valuation
--------------------------------------------------------------------------------

- Pre-money equity value of Aspire approximately $316 million.
- Combined company to be named 'Aspire Biopharma Holdings, Inc.' and list on Nasdaq under 'ASPH'.
- Existing Aspire shareholders expected to retain majority ownership after closing.
- Expected closing end of Q4 2024 or beginning of Q1 2025; subject to regulatory and stockholder approvals.
- Aspire's lead product Instaprin (soluble aspirin) targeting 505(b)(2) NDA with FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315224034714/0001493152-24-034714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315224034714/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-034714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer